IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-38892-w.html
   My bibliography  Save this article

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Author

Listed:
  • Spyros Chalkias

    (Moderna, Inc.)

  • Charles Harper

    (Meridian Clinical Research)

  • Keith Vrbicky

    (Meridian Clinical Research)

  • Stephen R. Walsh

    (Brigham and Women’s Hospital)

  • Brandon Essink

    (Meridian Clinical Research)

  • Adam Brosz

    (Meridian Clinical Research)

  • Nichole McGhee

    (Moderna, Inc.)

  • Joanne E. Tomassini

    (Moderna, Inc.)

  • Xing Chen

    (Moderna, Inc.)

  • Ying Chang

    (Moderna, Inc.)

  • Andrea Sutherland

    (Moderna, Inc.)

  • David C. Montefiori

    (Department of Surgery and Duke Human Vaccine Institute)

  • Bethany Girard

    (Moderna, Inc.)

  • Darin K. Edwards

    (Moderna, Inc.)

  • Jing Feng

    (Moderna, Inc.)

  • Honghong Zhou

    (Moderna, Inc.)

  • Lindsey R. Baden

    (Brigham and Women’s Hospital)

  • Jacqueline M. Miller

    (Moderna, Inc.)

  • Rituparna Das

    (Moderna, Inc.)

Abstract

We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received the mRNA-1273 primary series (100-µg) and mRNA-1273 first booster (50-µg) dose. Primary endpoints were safety, non-inferiority of the neutralizing antibody (nAb) and seroresponse against Omicron BA.1, superiority of the nAb response against Omicron-BA.1, and non-inferiority of the nAb response against ancestral SARS-CoV-2 for second boosters of mRNA-1273.214 versus mRNA-1273 at days 29 and 91. The key secondary endpoint was the seroresponse difference of mRNA-1273.214 versus mRNA-1273 against ancestral SARS-CoV-2 at days 29 and day 91. Participants were sequentially enrolled and dosed with 50-µg of mRNA-1273 (n = 376) or mRNA-1273.214 (n = 437) as second booster doses. Here we present day 91 post-booster results. In participants with no pre-booster, severe acute respiratory syndrome coronavirus 2-infection (SARS-CoV-2), mRNA-1273.214 elicited Omicron-BA.1-nAb titers (95% confidence interval [CI]) that were significantly higher (964.4 [834.4-1114.7]) than those of mRNA-1273 (624.2 [533.1-730.9]) and similar to those of mRNA-1273 against ancestral SARS-CoV-2 at day 91. mRNA-1273.214 also induced higher binding antibody responses against Omicron BA.1 and alpha, gamma and delta variants than mRNA-1273. Safety profiles were similar for both vaccines. The Omicron-BA.1 bivalent vaccine improved antibody responses compared to mRNA-1273 through 90 days post-booster.

Suggested Citation

  • Spyros Chalkias & Charles Harper & Keith Vrbicky & Stephen R. Walsh & Brandon Essink & Adam Brosz & Nichole McGhee & Joanne E. Tomassini & Xing Chen & Ying Chang & Andrea Sutherland & David C. Montefi, 2023. "Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19," Nature Communications, Nature, vol. 14(1), pages 1-7, December.
    • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-38892-w
    DOI: 10.1038/s41467-023-38892-w
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-38892-w
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-023-38892-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Yunlong Cao & Ayijiang Yisimayi & Fanchong Jian & Weiliang Song & Tianhe Xiao & Lei Wang & Shuo Du & Jing Wang & Qianqian Li & Xiaosu Chen & Yuanling Yu & Peng Wang & Zhiying Zhang & Pulan Liu & Ran A, 2022. "BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection," Nature, Nature, vol. 608(7923), pages 593-602, August.
    2. Wafaa B. Alsoussi & Sameer Kumar Malladi & Julian Q. Zhou & Zhuoming Liu & Baoling Ying & Wooseob Kim & Aaron J. Schmitz & Tingting Lei & Stephen C. Horvath & Alexandria J. Sturtz & Katherine M. McInt, 2023. "SARS-CoV-2 Omicron boosting induces de novo B cell response in humans," Nature, Nature, vol. 617(7961), pages 592-598, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Taha Y. Taha & Irene P. Chen & Jennifer M. Hayashi & Takako Tabata & Keith Walcott & Gabriella R. Kimmerly & Abdullah M. Syed & Alison Ciling & Rahul K. Suryawanshi & Hannah S. Martin & Bryan H. Bach , 2023. "Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    2. Guoli Shi & Tiansheng Li & Kin Kui Lai & Reed F. Johnson & Jonathan W. Yewdell & Alex A. Compton, 2024. "Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    3. Joseph A. Lewnard & Vennis Hong & Jeniffer S. Kim & Sally F. Shaw & Bruno Lewin & Harpreet Takhar & Sara Y. Tartof, 2023. "Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    4. Felix Dewald & Martin Pirkl & Martha Paluschinski & Joachim Kühn & Carina Elsner & Bianca Schulte & Jacqueline Knüfer & Elvin Ahmadov & Maike Schlotz & Göksu Oral & Michael Bernhard & Mark Michael & M, 2023. "Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    5. Anna R. Mäkelä & Hasan Uğurlu & Liina Hannula & Ravi Kant & Petja Salminen & Riku Fagerlund & Sanna Mäki & Anu Haveri & Tomas Strandin & Lauri Kareinen & Jussi Hepojoki & Suvi Kuivanen & Lev Levanov &, 2023. "Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    6. Zhennan Zhao & Yufeng Xie & Bin Bai & Chunliang Luo & Jingya Zhou & Weiwei Li & Yumin Meng & Linjie Li & Dedong Li & Xiaomei Li & Xiaoxiong Li & Xiaoyun Wang & Junqing Sun & Zepeng Xu & Yeping Sun & W, 2023. "Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    7. Haofeng Wang & Qi Yang & Xiaoce Liu & Zili Xu & Maolin Shao & Dongxu Li & Yinkai Duan & Jielin Tang & Xianqiang Yu & Yumin Zhang & Aihua Hao & Yajie Wang & Jie Chen & Chenghao Zhu & Luke Guddat & Hong, 2023. "Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    8. Yuta Tanoue & Cyrus Ghaznavi & Takayuki Kawashima & Akifumi Eguchi & Daisuke Yoneoka & Shuhei Nomura, 2022. "Changes in Health Care Access during the COVID-19 Pandemic: Estimates of National Japanese Data, June 2020–October 2021," IJERPH, MDPI, vol. 19(14), pages 1-12, July.
    9. Kuan-Ying A. Huang & Xiaorui Chen & Arpita Mohapatra & Hong Thuy Vy Nguyen & Lisa Schimanski & Tiong Kit Tan & Pramila Rijal & Susan K. Vester & Rory A. Hills & Mark Howarth & Jennifer R. Keeffe & Ale, 2023. "Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    10. Xiaolei Wang & Terrence Tsz-Tai Yuen & Ying Dou & Jingchu Hu & Renhao Li & Zheng Zeng & Xuansheng Lin & Huarui Gong & Celia Hoi-Ching Chan & Chaemin Yoon & Huiping Shuai & Deborah Tip-Yin Ho & Ivan Fa, 2023. "Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    11. Saya Moriyama & Yuki Anraku & Shunta Taminishi & Yu Adachi & Daisuke Kuroda & Shunsuke Kita & Yusuke Higuchi & Yuhei Kirita & Ryutaro Kotaki & Keisuke Tonouchi & Kohei Yumoto & Tateki Suzuki & Taiyou , 2023. "Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    12. Wanbo Tai & Kai Yang & Yubin Liu & Ruofan Li & Shengyong Feng & Benjie Chai & Xinyu Zhuang & Shaolong Qi & Huicheng Shi & Zhida Liu & Jiaqi Lei & Enhao Ma & Weixiao Wang & Chongyu Tian & Ting Le & Jin, 2023. "A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    13. Yubin Liu & Ziyi Wang & Xinyu Zhuang & Shengnan Zhang & Zhicheng Chen & Yan Zou & Jie Sheng & Tianpeng Li & Wanbo Tai & Jinfang Yu & Yanqun Wang & Zhaoyong Zhang & Yunfeng Chen & Liangqin Tong & Xi Yu, 2023. "Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    14. Emanuele Andreano & Ida Paciello & Giulio Pierleoni & Giuseppe Maccari & Giada Antonelli & Valentina Abbiento & Piero Pileri & Linda Benincasa & Ginevra Giglioli & Giulia Piccini & Concetta De Santi &, 2023. "mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 and BA.5," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
    15. Rebecca Urschel & Saskia Bronder & Verena Klemis & Stefanie Marx & Franziska Hielscher & Amina Abu-Omar & Candida Guckelmus & Sophie Schneitler & Christina Baum & Sören L. Becker & Barbara C. Gärtner , 2024. "SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    16. Shaofeng Deng & Ying Liu & Rachel Chun-Yee Tam & Pin Chen & Anna Jinxia Zhang & Bobo Wing-Yee Mok & Teng Long & Anja Kukic & Runhong Zhou & Haoran Xu & Wenjun Song & Jasper Fuk-Woo Chan & Kelvin Kai-W, 2023. "An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    17. Hung Fu Tseng & Bradley K. Ackerson & Katia J. Bruxvoort & Lina S. Sy & Julia E. Tubert & Gina S. Lee & Jennifer H. Ku & Ana Florea & Yi Luo & Sijia Qiu & Soon Kyu Choi & Harpreet S. Takhar & Michael , 2023. "Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    18. Andrew C. Hunt & Bastian Vögeli & Ahmed O. Hassan & Laura Guerrero & Weston Kightlinger & Danielle J. Yoesep & Antje Krüger & Madison DeWinter & Michael S. Diamond & Ashty S. Karim & Michael C. Jewett, 2023. "A rapid cell-free expression and screening platform for antibody discovery," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    19. Jia Wei & Nicole Stoesser & Philippa C. Matthews & Tarnjit Khera & Owen Gethings & Ian Diamond & Ruth Studley & Nick Taylor & Tim E. A. Peto & A. Sarah Walker & Koen B. Pouwels & David W. Eyre, 2024. "Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    20. Laura Solforosi & Lea M. M. Costes & Jeroen T. B. M. Tolboom & Katherine McMahan & Tochi Anioke & David Hope & Tetyana Murdza & Michaela Sciacca & Emily Bouffard & Julia Barrett & Cindy Wu & Nicole Ha, 2023. "Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques," Nature Communications, Nature, vol. 14(1), pages 1-14, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-38892-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.